In vitro mutagenicity and blood compatibility of paclitaxel and curcumin in poly (dl-lactide-co-glicolide) films

Curcumin is considered to be a potential component for drug-eluting stents due to its anti-inflammatory properties. In this study we compared the mutagenicity and blood compatibility of curcumin to first generation drug eluting stent components: paclitaxel and sirolimus. The Ames test was used to assess mutagenicity. Blood compatibility was tested by measuring platelet activation and fibrinogen adsorption on poly (dl-lactide-co-glycolide, PLGA) films. We discovered that there was no significant increase in the number of revertants/plate following treatment with curcumin (up to 0.5 mg/plate) or sirolimus (up to 0.5 μg/plate). However, a significant induction in the frequency of bacterial his+ revertant colonies by paclitaxel at concentrations of 0.02, 0.05, 0.1, 0.2 and 0.5 μg/plate was observed. We also discovered a significant reduction in platelet activation by PLGA films containing 30% and 50% by weight curcumin. A similar reduction in platelet activation was also observed for PLGA films containing 1% by weight paclitaxel. In addition, we observed an increase of fibrinogen adsorption to PLGA-films containing curcumin. This would compromise the potential use of curcumin as a component of drug-eluting stents. Moreover, our data challenges the current view that paclitaxel does not significantly induce mutagenesis.

► High curcumin was not mutagenic in the Ames test. ► Paclitaxel has shown to be mutagenic in the Ames test. ► Curcumin reduces platelet activation in PLGA films. ► Curcumin promotes fibrinogen adsorption in PLGA films.